Lectures and seminars Faculty event with Konstantin Carlberg

Abstract

All healthy individuals have residual DNA from dying cells in the blood so called cell-free DNA. In patients with cancer, a fraction of the cell-free DNA originates from the cancer cells which is called circulating tumor DNA (ctDNA). The ProBio trial involves metastatic hormone-sensitive (mHSPC) or metastatic castration-resistant (mCRPC) prostate cancer patients which are randomized by prospective profiling of ctDNA. The purpose of the trial is to identify treatment predictive biomarkers and evaluate if biomarker guided treatment selection can improve outcomes. However, a large fraction of mHSPC patients have low ctDNA fraction which prevents detection of certain biomarkers. A potential remedy is sequencing the diagnostic biopsies instead of ctDNA in cases with low tumor burden. The purpose of this project is to perform profiling of ctDNA and diagnostic biopsies in order to check whether the cancer clones represented in the biopsy material is found also in the ctDNA. In other words, genomic alterations found in the tissue biopsies could act as a proxy for metastasis. Apart from that, this study aims to evaluate the usefulness of selected biopsies contra mixtures of biopsy material which would aid in finding a pragmatic procedure for analyzing the cancer genome of mHSPC patients in the ProBio trial.

Welcome to have lunch in Ljusgården at 12:00!